Related Experiment Video

Updated: Jul 5, 2026

Development of a Hepatitis B Virus Reporter System to Monitor the Early Stages of the Replication Cycle
09:35

Development of a Hepatitis B Virus Reporter System to Monitor the Early Stages of the Replication Cycle

Published on: February 1, 2017

13.2K

Hepatitis B: Model Systems and Therapeutic Approaches

Xiaoxiao Yu1, Yating Gao1, Xin Zhang1

  • 1Laboratory of Cellular Immunity, Shuguang Hospital, Affiliated to Shanghai University of Traditional Chinese Medicine, Shanghai, China.

Journal of Immunology Research
|May 15, 2024
PubMed

Insights

Hepatitis B virus (HBV) infection remains a global health challenge, with current treatments unable to fully eradicate the virus. This review explores HBV models and novel therapeutic strategies to advance effective anti-HBV medicine.

Area of Science:

  • Hepatology and Virology
  • Drug Discovery and Development

Background:

  • Hepatitis B virus (HBV) infection is a leading cause of liver cirrhosis and hepatocellular carcinoma globally.
  • Current antiviral therapies can inhibit HBV replication but not achieve complete eradication.
  • Effective cellular and animal models are crucial for advancing anti-HBV drug development.

Purpose of the Study:

  • To review existing cellular and animal models for studying HBV infection.
  • To survey novel therapeutic strategies and advancements in HBV treatment.
  • To provide insights for discovering new pharmaceutical interventions against HBV.

Main Methods:

  • Review of established cell culture systems (HepG2.2.15, HepAD38, HepaRG, primary human hepatocytes) for HBV research.
  • Analysis of extensively studied mouse models for HBV infection.
  • Survey of current HBV therapeutics research, including entry inhibitors, cccDNA-targeting strategies, RNA interference, TLR agonists, and Traditional Chinese Medicine (TCM).

Main Results:

  • Various cell culture systems and mouse models have significantly advanced the understanding of HBV replication, expression, and antiviral drug evaluation.
  • Current research encompasses diverse therapeutic approaches targeting multiple facets of the HBV life cycle.
  • Novel immunomodulatory strategies and TCM show promise in HBV therapeutics.

Conclusions:

  • Existing HBV model systems have limitations but have been instrumental in research.
  • Advancements in therapeutic modalities offer new avenues for HBV treatment.
  • Further exploration of these models and therapies is essential for developing curative interventions for HBV infection.

More Related Videos

Modeling Hepatitis B Virus Infection in Non-Hepatic 293T-NE-3NRs Cells09:02

Modeling Hepatitis B Virus Infection in Non-Hepatic 293T-NE-3NRs Cells

Published on: June 5, 2020

7.4K
A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target11:34

A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target

Published on: May 10, 2022

2.2K

Related Concept Videos

Physiological Pharmacokinetic Models: Incorporating Hepatic Transporter-Mediated Clearance01:07

Physiological Pharmacokinetic Models: Incorporating Hepatic Transporter-Mediated Clearance

Drug transporters are critical in drug absorption, distribution, and excretion processes. They should be included in physiological-based pharmacokinetic (PBPK) models, which help predict human drug disposition. However, predicting this is challenging during drug development, especially when liver transport is involved. However, with a realistic representation of body transport processes, an accurate model may be possible.
A recent model describes pravastatin's hepatobiliary excretion, mediated...
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test01:22

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess the...
Hepatitis01:25

Hepatitis

Hepatitis is an inflammatory condition of the liver most commonly caused by hepatotropic viruses (A–E), though non-infectious causes such as alcohol and drugs also exist.Hepatitis AHepatitis A virus (HAV) is a non-enveloped RNA virus of the Picornaviridae family. It is primarily transmitted via the fecal-oral route, typically through ingestion of contaminated food or water. After ingestion, HAV enters the bloodstream through the oropharynx or intestinal epithelium and reaches the liver. The...
Viral Hepatitis I: Introduction01:28

Viral Hepatitis I: Introduction

Viral hepatitis is an inflammatory condition of the liver caused by infection with hepatotropic viruses, most commonly hepatitis A, B, C, D, and E. Despite variations in structure and transmission, all viruses mentioned infect hepatocytes and provoke immune responses that can hinder liver function. Additionally, some non-hepatotropic viruses can also lead to hepatic inflammation.Hepatitis A VirusHepatitis A virus (HAV) is transmitted through the fecal–oral route, typically by ingestion of food...